HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper
HempFusion Wellness Inc. (TSE:CBD.U) (OTCMKTS:CBDHF), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce it has completed, in collaboration with the Inflammatory Markers Laboratory (“IML”) located in Wichita, Kansas, a pilot study that assessed the effect of the HempFusion formulation CBD Capsules® (HempFusion 20mg CBD capsules with botanical terpenes) as it relates to a combination of anti-inflammatories in lowering the results of the chronic inflammation test (which measures urinary 11-dehydro thromboxane B2, the stable end product of intracellular thromboxane metabolism that has been shown to correlate with inflammation) and has released a white paper titled “Oral Formulation May Modulate Thromboxane Production”i.
Results of the pilot study have shown potential promise in the area of inflammatory markers and possible effects on exaggerated inflammation.
“Our laboratory has demonstrated the effectiveness of numerous products in reducing thromboxane production,” commented Gordon Ens, Director of IML. “I was pleased to see a CBD product show such a significant reduction of thromboxane in this pilot trial.”
The white paper, expected to be published shortly, is co-authored by Gordon Ens, Director of IML and George Fritsma, Professor at University of Alabama, and illustrates the potential of tracking and elucidating biomarkers sensitive to inflammation in addition to how novel compounds and formulas modulate the expression of these markers.
We are committed to furthering research in the area of hemp-derived CBD and this pilot trial and soon to be published white paper reinforces our continued focus on the safe and effective use of hemp-derived CBD products.Jason Mitchell, N.D., HempFusion’s Co-Founder and Chief Executive Officer commented,
HempFusion is dedicated to research related to toxicology safety, which is evident through its involvement and co-sponsoring of the ValidCare Human Observational Safety Study, what is believed to be the largest CBD toxicology study of its kind ever completed to date. HempFusion continues to focus on research & development, pilot studies, and clinical trials, to advance the science of CBD.
HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex™ and are available in-store or by visiting HempFusion online at www.hempfusion.com or www.probulin.com.
Follow HempFusion on Twitter, Facebook and Instagram and Probulin on Twitter, Facebook and Instagram.
To view the original press release in its entirety click here